Business context and reporting period
The supplied filing is Oncocyte Corporation’s unaudited Form 10-Q for the quarter and six months ended June 30, 2021; it is not a filing under the metadata name “Insight Molecular Diagnostics Inc.” Oncocyte develops and commercializes molecular diagnostic tests and provides pharmaceutical services. Its products and programs include DetermaRx, DetermaIO and tests acquired with Chronix.
During the period, Oncocyte acquired the remaining interests in Razor Genomics, bringing DetermaRx fully in-house, and acquired Chronix Biomedical, adding transplant and immunotherapy-monitoring test programs. The acquisitions materially changed the business and the comparability of revenue and expenses with 2020.
Financial results and position
Amounts below are in millions of dollars except per-share data. Parentheses indicate losses or cash outflows.
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | 2.030 | 0.143 | 3.154 | 0.158 |
| Gross profit (loss) | (0.394) | (0.222) | (0.315) | (0.380) |
| Operating loss | (13.568) | (8.768) | (24.928) | (17.200) |
| Net loss | (10.493) | (9.108) | (14.412) | (16.840) |
| Net loss per share, basic and diluted | (0.12) | (0.14) | (0.17) | (0.26) |
| Operating cash flow | Not presented quarterly | Not presented quarterly | (17.926) | (13.831) |
- Q2 revenue comprised DetermaRx testing of $0.645 million, Pharma Services of $0.168 million and licensing of $1.217 million. Licensing included a $1.0 million performance milestone and $0.217 million of Chronix deferred revenue recognized.
- Gross margin remained negative: Q2 gross loss was $0.394 million on $2.030 million revenue, including $1.074 million of acquired-intangible amortization in cost of revenue.
- Operating expenses for the first half were $24.613 million, including R&D of $5.898 million, sales and marketing of $4.927 million, G&A of $12.698 million and $1.090 million of increased contingent-consideration fair value.
- The first-half net loss improved year over year despite a higher operating loss, primarily alongside a $9.358 million income tax benefit related to acquisition-generated deferred tax liabilities and a $1.141 million gain from forgiveness of the PPP loan.
- Cash and cash equivalents were $46.469 million at June 30, 2021, versus $7.143 million at December 31, 2020. Marketable equity securities were $1.062 million; restricted cash was $1.700 million. Current assets were $49.995 million and current liabilities $19.775 million.
- First-half investing cash outflow was $13.166 million; financing cash inflow was $70.418 million, mainly from common-stock sales. Cash, cash equivalents and restricted cash increased by $39.326 million to $48.169 million.
- Loans payable totaled about $2.041 million, excluding lease liabilities. Lease liabilities totaled approximately $4.632 million. The balance sheet also included $50.505 million of noncurrent contingent consideration and $11.734 million of current accrued acquisition liabilities.
Material changes versus prior comparable periods
- First-half revenue rose $2.996 million from 2020, reflecting DetermaRx growth, Pharma Services and licensing revenue. DetermaRx contributed 40% of first-half revenue versus 7% a year earlier; Pharma Services contributed 22% versus 93%, and licensing contributed 38% versus none.
- Q2 revenue increased by $1.887 million year over year. DetermaRx revenue was $0.645 million versus $0.010 million; licensing added $1.217 million, while Pharma Services rose to $0.168 million from $0.133 million.
- First-half operating loss widened by $7.728 million. Higher sales and marketing, G&A, cost of revenue and acquisition-related amortization outweighed lower comparative net loss.
- G&A included $2.5 million of severance expense associated with the Chronix acquisition. Oncocyte recorded $1.381 million of acquired-intangible amortization for the first half, compared with $0.037 million in 2020.
- Oncocyte issued substantially more shares: 90.316 million were outstanding at June 30, 2021, compared with 69.117 million at year-end 2020. First-half equity financing provided $70.418 million net cash overall from financing activities.
Outlook, risks and unusual items
- Management said cash, cash equivalents and marketable securities were expected to fund current operations for at least 12 months from the issuance date of the financial statements. It also said additional capital would be needed until operating revenue can cover expenses; future equity issuance may dilute shareholders, and financing may not be available on favorable terms.
- No revenue or earnings guidance was provided. Management expected continued operating losses and negative cash flows, and significant future R&D and sales and marketing spending. It planned to continue DetermaRx commercialization and develop DetermaIO, DetermaTx, DetermaMx and DetermaCNI.
- COVID-19 could defer lung-cancer surgeries and pharmaceutical clinical trials, limiting demand for testing and Pharma Services; it could also constrain outreach, operations, supply chains and access to capital. Management said the ultimate effects were uncertain.
- Commercialization depends on clinical evidence, test adoption and reimbursement coverage, including Medicare and private payers. DetermaRx revenue recognition for non-Medicare payers remained cash-based where collection could not be reliably estimated. First-half revenue also had customer and milestone concentration: one licensing customer accounted for 32% of revenue.
- Acquisition consideration creates significant potential obligations. Chronix contingent consideration had an acquisition-date fair value of $42.295 million, and Insight-related contingent consideration was $8.210 million at June 30, 2021. Outcomes depend on milestones, revenue and valuation assumptions; future payments could compete with operating investment.
- The PPP loan was forgiven in May 2021, generating a $1.141 million gain. The $9.358 million first-half tax benefit was acquisition-related; a full valuation allowance remained for other deferred tax assets. The filing reported no material litigation, no defaults and no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the registrant identity and period: the filing is Oncocyte Corporation’s Q2 2021 10-Q, despite the different company name in the request metadata.
- Track DetermaRx test volume, collections and reimbursement coverage, especially Medicare Advantage and other payer arrangements, and assess whether revenue growth can improve gross margins.
- Assess how repeatable licensing milestones and Pharma Services activity are; Q2 revenue depended heavily on licensing, and the filing describes period-to-period variability and customer concentration.
- Review cash burn, subsequent financing and dilution. The filing reports $17.926 million of operating cash use in the first half and approximately $6.24 million gross ATM proceeds in July 2021.
- Monitor Chronix and Insight contingent payments, acquisition liabilities and milestone or royalty assumptions, as well as clinical, regulatory, reimbursement and impairment risks for acquired test assets.